OVID
NASDAQ · Biotechnology
Ovid Therapeutics Inc
$2.44
+0.01 (+0.41%)
Financial Highlights (FY 2026)
Revenue
18.59M
Net Income
-44,616,919
Gross Margin
—
Profit Margin
-240.1%
Rev Growth
+69.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 35.9% | 35.9% |
| Operating Margin | -585.2% | -526.7% | -33.9% | -31.3% |
| Profit Margin | -240.1% | -228.1% | -26.8% | -31.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 18.59M | 10.99M | 31.11M | 33.06M |
| Gross Profit | — | — | 11.16M | 11.86M |
| Operating Income | -108,772,493 | -57,895,347 | -10,543,713 | -10,340,763 |
| Net Income | -44,616,919 | -23,747,842 | -8,350,078 | -10,285,734 |
| Gross Margin | — | — | 35.9% | 35.9% |
| Operating Margin | -585.2% | -526.7% | -33.9% | -31.3% |
| Profit Margin | -240.1% | -228.1% | -26.8% | -31.1% |
| Rev Growth | +69.1% | +69.1% | +19.5% | +23.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 32.20M | 24.28M |
| Total Equity | — | — | 114.62M | 121.51M |
| D/E Ratio | — | — | 0.28 | 0.20 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -108,028,858 | -60,693,958 | -13,566,183 | -16,328,398 |
| Free Cash Flow | — | — | -8,976,737 | -6,780,942 |